January 24, 2020 06:17 AM ESTUpdated 06:42 AM

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

Natalie Grover

Reporter

Just weeks after Merck’s star checkpoint inhibitor Keytruda secured FDA approval for a subset of bladder cancer patients, Swiss competitor Roche’s Tecentriq has failed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

Natalie Grover

Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Breaking down silos with a new quantitative approach to drug development

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Roche's checkpoint player Tecentriq flops in another bladder cancer subset